Metronidazole
Brand names: Flagyl, Metrolyl (IV)
Metronidazole is a nitroimidazole antimicrobial used to treat anaerobic bacterial infections and certain protozoal infections such as amoebiasis, giardiasis and trichomoniasis, and is a mainstay of Clostridioides difficile and intra-abdominal infection regimens.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is reduced intracellularly by anaerobic organisms to reactive nitroso intermediates that cause DNA strand breakage and bacterial cell death, giving it selective activity against anaerobes and microaerophiles.
Prescribing in practice
- Warn patients to avoid alcohol during treatment and for a short period afterwards because of a potential disulfiram-like reaction with flushing, nausea and vomiting.
- It potentiates warfarin and other coumarin anticoagulants, so monitor INR closely when co-prescribed.
- Prolonged or high-dose courses carry a risk of peripheral and central neuropathy, so avoid unnecessarily long treatment.
Monitoring
For short courses no routine monitoring is needed, but check for neurological symptoms during prolonged therapy and monitor INR in patients taking anticoagulants.
Counselling the patient
- Do not drink alcohol while taking this medicine and avoid it for a couple of days after finishing the course.
- Complete the full course even if you feel better.
- Report any numbness, tingling or unsteadiness, which should be reviewed.
Evidence & guidelines
Metronidazole is established UK standard-of-care for anaerobic and protozoal infections and features in NICE and national antimicrobial guidance.
Reference: NICE NG199 (C. difficile); BASHH Bacterial Vaginosis Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023